India clears Ipca's up to 59.38% buyout of Unichem Laboratories
What's the deal? The Competition Commission of India has approved Ipca Laboratories'Dealroom has a profile for this one. Try Dealroom → acquisition of up to 59.38% of Unichem LaboratoriesDealroom has a profile for this one. Try Dealroom →. Both are pharmaceutical companies, and the deal value was not disclosed.
How is it structured? Ipca will buy roughly 33.38% of Unichem's fully diluted equity voting share capital through a share purchase agreement. Because that exceeds 25% in a listed company, Ipca must also make an open offer for up to 26% of Unichem's shares under Securities and Exchange Board of India takeover rules, taking its total stake to as much as 59.38%.
What does each side bring? Ipca makes formulations and active pharmaceutical ingredients across therapeutic segments. Unichem sells formulations, active pharmaceutical ingredients, intermediates, and contract-manufactured finished dosages globally.
What's the catch? The Competition Commission of India cleared the combination subject to compliance with an undertaking the parties voluntarily submitted. A detailed order will follow.
The signal: The deal gives Ipca majority control of a global-facing peer, consolidating formulations and active pharmaceutical ingredient capacity under one owner in India's crowded pharmaceutical sector.
Read more: observervoice.com
Image credit: Monash Public Library Service
